Pneumococcal disease is an infection caused by the Streptococcus pneumoniae (S. pneumoniae) bacterium, also known as pneumococcus. Infection can result in pneumonia, infection of the blood (bacteremia ...

The Australian government announced last week there's a new vaccine for pneumococcal disease on the National Immunization Program for all children. This vaccine replaces previously listed pneumococcal ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia. An ...

Despite early and adequate treatment, there can still be serious and potentially life-threatening complications arising from pneumococcal infection. Doctors will usually prescribe antibiotics for ...

After the onset of serious pneumococcal infections, patients are at a significantly increased risk of having a heart attack, according to a Vanderbilt study published in the journal Clinical ...

In recent decades, there has been an increase in the number of novel viral infections. One such novel pathogen is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of ...

Oct 24 (Reuters) - The U.S. Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease. The ...

A new study by University of Liverpool researchers reveals how resistance to bacteremic pneumonia is provided by a unique subset of lung T regulatory cells. The Bacterial Pathogenesis and Immunity ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE ® ...

REDMOND, Wash.--(BUSINESS WIRE)--Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has begun in Halifax, ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...

The increase in invasive pneumococcal disease across Europe is driven by Streptococcus pneumoniae, which also causes pneumonia and acute otitis media that can progress to invasive infections. Nearly ...